Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
7.40
+0.10 (1.37%)
Sep 17, 2025, 12:30 PM EDT - Market open
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Fulcrum Therapeutics stock have a consensus rating of "Buy" and an average price target of $7.13, which forecasts a -3.65% decrease in the stock price over the next year. The lowest target is $2.00 and the highest is $12.
Price Target: $7.13 (-3.65%)
Analyst Consensus: Buy
* Price targets were last updated on Jul 30, 2025.
Analyst Ratings
The average analyst rating for Fulcrum Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 1 | 1 | 1 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 5 | 3 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $4 → $5 | Hold | Maintains | $4 → $5 | -32.43% | Jul 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $4 → $12 | Hold → Strong Buy | Upgrades | $4 → $12 | +62.16% | Jul 29, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $9 | Buy | Maintains | $6 → $9 | +21.62% | May 29, 2025 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $4 → $12 | Hold → Buy | Upgrades | $4 → $12 | +62.16% | May 23, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold → Buy Upgrades $10 | Hold → Buy | Upgrades | $10 | +35.14% | May 15, 2025 |
Financial Forecast
Revenue This Year
n/a
from 80.00M
Revenue Next Year
n/a
EPS This Year
-1.17
from -0.16
EPS Next Year
-1.22
from -1.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.11 | -1.07 | |||
| Avg | -1.17 | -1.22 | |||
| Low | -1.22 | -1.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.